CTOs on the Move

Veristat

www.veristat.com

 
Veristat, a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.veristat.com
  • 134 Turnpike Road Suite 200
    Southborough, MA USA 01772
  • Phone: 508.429.7340

Executives

Name Title Contact Details

Similar Companies

BioFX Laboratories

BioFX Laboratories is a Owings Mills, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abbott

Abbott is a global healthcare company that conducts innovative research and manufactures products for human health through every life stage. They bring new products and technologies to the world in nutrition, diagnostics, medical devices and branded ge...

Meyer Pharmaceuticals (Main)

Meyer Pharmaceuticals (Main) is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Serán Bioscience,

Serán Bioscience is a contract development and manufacturing organization (CDMO) that provides drug development services to the pharmaceutical industry, including chemistry, formulation, spray drying, dosage form, analytical, and GMP manufacturing serv...

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.